July 13, 2015 - For people who use cocaine, stopping or reducing cocaine use is associated with decreased levels of endothelin-1 (ET-1)--a protein that plays a key role in the development of coronary artery disease, reports a study in the Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine. The journal is published by Wolters Kluwer.
The findings help in understanding the high rate of atherosclerosis (hardening of the arteries) associated with cocaine use, according to the report by Dr. Shenghan Lai and colleagues of Johns Hopkins School of Medicine, Baltimore. Stopping or reducing cocaine use may prevent the endothelial damage that represents the first step in the development of atherosclerosis, the study suggests.
Stopping Cocaine Use May Lower ET-1--Possibly Slowing Atherosclerosis Progression
The study included 57 African American patients with long-term cocaine use, most of whom had HIV infection. The patients were drawn from a study evaluating incentives to abstain from cocaine use. On initial imaging scans (CT angiography), all had less than 50 percent stenosis (narrowing) of the coronary arteries.
Funded by the National Institute on Drug Abuse, part of the National Institutes of Health, the study focused on how stopping or reducing cocaine use affected levels of the cardiovascular risk marker ET-1. In previous research, Dr. Lai and colleagues found that ET-1 levels are "remarkably higher" in chronic cocaine users.
Endothelin-1 is believed to play a key role in damage to the endothelium--the thin cell layer lining the inside of blood vessels. Endothelial dysfunction is the first step in the development of atherosclerosis.
At six months' follow-up, 28 of the patients were abstinent from cocaine, as confirmed by urine testing. This group had significantly reduced ET-1 levels, compared to those who continued to use cocaine.
Patients who reduced but did not stop their cocaine use (fewer days of use) also had lower ET-1 levels. This difference was significant after adjusting for other factors, including previous cardiovascular risk and initial ET-1 level.
Follow-up CT angiography scans were performed to assess the progression of atherosclerotic plaques in the patients' coronary arteries. The results showed a lower likelihood of coronary plaque progression for patients who stopped using cocaine--about two-thirds lower than for continued users. In this preliminary study, the difference in plaque progression wasn't statistically significant.
Cocaine users are at high risk of premature atherosclerosis. Despite extensive research, the mechanisms linking cocaine use with the development and progression of atherosclerosis haven't been well explained.
"The findings of this study revealed a possible association of cocaine abstinence/reduction with lowered ET-1 levels, which suggests that such changes in cocaine use might be beneficial for preventing endothelial damage," Dr. Lai and colleagues conclude. They emphasize that more research will be needed to determine if the lower levels of endothelial damage markers reduce the high rates of cardiovascular disease and death associated with cocaine use. The researchers also suggest further studies to assess whether changes in ET-1 levels could be a useful marker of cocaine abstinence and reduction in cocaine use.
Article: "Cocaine Abstinence and Reduced Use Associated With Lowered Marker of Endothelial Dysfunction in Africa Americans: A Preliminary Study" (doi: 10.1097/ADM.0000000000000140)
About Journal of Addiction Medicine
The mission of Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine, is to promote excellence in the practice of addiction medicine and in clinical research as well as to support Addiction Medicine as a mainstream medical specialty. Published quarterly, the Journal is designed for all physicians and other mental health professionals who need to keep up-to-date with the treatment of addiction disorders. Under the guidance of an esteemed Editorial Board, peer-reviewed articles published in the Journal focus on developments in addiction medicine as well as on treatment innovations and ethical, economic, forensic, and social topics.
About The American Society of Addiction Medicine
The American Society of Addiction Medicine is a national medical specialty society of over 3,200 physicians and associated health professionals. Its mission is to increase access to and improve the quality of addiction treatment, to educate physicians, and other health care providers and the public, to support research and prevention, to promote the appropriate role of the physician in the care of patients with addictive disorders, and to establish addiction medicine as a specialty recognized by professional organizations, governments, physicians, purchasers and consumers of health care services and the general public. ASAM was founded in 1954, and has had a seat in the American Medical Association House of Delegates since 1988. Follow ASAM's official Twitter handle: @ASAMorg
About Wolters Kluwer
Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2014 annual revenues of €3.7 billion. The group serves customers in over 170 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on NYSE Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
For more information about our products and organization, visit http://www.